Compare GPOR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPOR | ACAD |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.2B |
| IPO Year | N/A | 2004 |
| Metric | GPOR | ACAD |
|---|---|---|
| Price | $216.66 | $26.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $221.22 | $29.24 |
| AVG Volume (30 Days) | 259.7K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | N/A | ★ 1.54 |
| Revenue | ★ $1,231,668,000.00 | $1,047,118,000.00 |
| Revenue This Year | $57.17 | $15.16 |
| Revenue Next Year | $8.75 | $11.42 |
| P/E Ratio | ★ N/A | $16.79 |
| Revenue Growth | ★ 38.91 | 12.69 |
| 52 Week Low | $153.27 | $13.40 |
| 52 Week High | $225.78 | $26.65 |
| Indicator | GPOR | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 72.80 |
| Support Level | $212.34 | $22.81 |
| Resistance Level | $225.78 | $25.20 |
| Average True Range (ATR) | 6.90 | 0.85 |
| MACD | -0.27 | 0.24 |
| Stochastic Oscillator | 61.17 | 99.25 |
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.